$294.57 Million in Sales Expected for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) This Quarter

Brokerages predict that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will post $294.57 million in sales for the current quarter, Zacks Investment Research reports. Eleven analysts have provided estimates for Neurocrine Biosciences’ earnings. The lowest sales estimate is $285.94 million and the highest is $304.00 million. Neurocrine Biosciences posted sales of $258.50 million during the same quarter last year, which would indicate a positive year over year growth rate of 14%. The company is expected to issue its next quarterly earnings report on Monday, November 8th.

On average, analysts expect that Neurocrine Biosciences will report full-year sales of $1.14 billion for the current financial year, with estimates ranging from $1.09 billion to $1.16 billion. For the next financial year, analysts expect that the business will report sales of $1.42 billion, with estimates ranging from $1.31 billion to $1.51 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Monday, August 2nd. The company reported $0.43 EPS for the quarter, missing analysts’ consensus estimates of $0.52 by ($0.09). The firm had revenue of $288.90 million for the quarter, compared to analyst estimates of $274.47 million. Neurocrine Biosciences had a return on equity of 33.04% and a net margin of 35.34%.

NBIX has been the subject of a number of research reports. Zacks Investment Research upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, August 18th. Canaccord Genuity downgraded Neurocrine Biosciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $122.00 to $108.00 in a research note on Friday, August 6th. The Goldman Sachs Group started coverage on Neurocrine Biosciences in a research note on Tuesday, May 18th. They issued a “neutral” rating and a $108.00 target price for the company. Morgan Stanley dropped their target price on Neurocrine Biosciences from $116.00 to $110.00 and set an “overweight” rating on the stock in a report on Wednesday, August 4th. Finally, HC Wainwright reissued a “buy” rating and set a $140.00 target price on shares of Neurocrine Biosciences in a report on Friday, July 16th. Seven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $119.60.

In related news, insider Eric Benevich sold 5,628 shares of the business’s stock in a transaction on Monday, August 16th. The stock was sold at an average price of $89.62, for a total value of $504,381.36. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Malcolm Lloyd-Smith sold 16,709 shares of the business’s stock in a transaction on Tuesday, July 27th. The stock was sold at an average price of $93.80, for a total value of $1,567,304.20. Following the completion of the transaction, the insider now directly owns 15,801 shares in the company, valued at approximately $1,482,133.80. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

A number of institutional investors have recently bought and sold shares of NBIX. CWM LLC boosted its stake in shares of Neurocrine Biosciences by 315.6% in the 1st quarter. CWM LLC now owns 374 shares of the company’s stock valued at $36,000 after purchasing an additional 284 shares during the last quarter. Berman Capital Advisors LLC boosted its stake in Neurocrine Biosciences by 139.0% during the 2nd quarter. Berman Capital Advisors LLC now owns 411 shares of the company’s stock worth $39,000 after acquiring an additional 239 shares during the last quarter. KB Financial Partners LLC bought a new position in Neurocrine Biosciences during the 1st quarter worth approximately $43,000. Credit Agricole S A bought a new position in Neurocrine Biosciences during the 1st quarter worth approximately $49,000. Finally, Truvestments Capital LLC lifted its stake in Neurocrine Biosciences by 178.1% in the first quarter. Truvestments Capital LLC now owns 773 shares of the company’s stock valued at $75,000 after buying an additional 495 shares in the last quarter. Institutional investors and hedge funds own 95.99% of the company’s stock.

Shares of NBIX traded up $1.42 during trading on Friday, reaching $96.04. The company’s stock had a trading volume of 2,087 shares, compared to its average volume of 900,142. The company has a market cap of $9.08 billion, a price-to-earnings ratio of 25.44 and a beta of 0.73. The company has a fifty day moving average of $94.07 and a two-hundred day moving average of $95.13. The company has a quick ratio of 5.08, a current ratio of 5.21 and a debt-to-equity ratio of 0.26. Neurocrine Biosciences has a twelve month low of $84.77 and a twelve month high of $120.27.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm’s product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W.

Further Reading: What are the advantages to having securities held in street name?

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.